EyePoint Pharmaceuticals Report – GuruFocus.com
WATERTOWN, Mass., July 18 12, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company engaged in the development and commercialization of therapeutic products to help improve the lives of patients with serious eye disorders, today announced that the company granted non-statutory stock options to new employees as incentives outside of the company’s 2016 long-term incentive plan pursuant to NASDAQ listing rule 5635(c)(4) .
The Company has granted stock options to purchase up to an aggregate of 18,000 shares of EyePoint Pharmaceuticals common stock to nine new employees. The stock options were granted on July 15, 2022. The grants were approved by the Compensation Committee and made as an incentive for each employee entering the employ of EyePoint Pharmaceuticals in accordance with the stock listing rule. NASDAQ 5635(c)(4). The option grants have an exercise price of $9.91 per share, the closing price of EyePoint Pharmaceuticals common stock on July 15, 2022. The options have a term of ten years and vest over four years. , with 25% of the initial number of shares. vested on the first anniversary of the relevant employee’s grant date and the balance vested in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continuous service with EyePoint Pharmaceuticals through the applicable vesting dates.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (EYPT) is a pharmaceutical company engaged in the development and commercialization of therapeutic products to help improve the lives of patients with serious eye disorders. The Company’s pipeline relies on its wholly owned Durasert® technology for prolonged intraocular drug delivery, including EYP-1901, an investigational prolonged intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely delivered to thousands of patient eyes through four US FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis of the posterior segment of the eye, currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
For EyePoint Pharmaceuticals:
Green Room Communications